Axitinib plus Pembrolizumab Is Effective in Renal Cell Carcinoma [Clinical Trials]

Axitinib plus pembrolizumab has a 73% response rate in previously untreated advanced renal cell carcinoma.

from Cancer via ola Kala on Inoreader https://ift.tt/2pY4UAF
via IFTTT